TABLE 1.

Bacterial isolates of MRSA USA300 collected during the 10-day HFIM investigating a 2-g q12h vancomycin regimen^a

Strain	Time (h) of VAN 2-g q12h exposure	MIC (mg/liter)
		VAN	LZD	DAP	RIF	LEV	CIP	GEN	NAF
LAD201	0 (baseline)	1	2	0.5	0.015	8	32	1	32
LAD202	24	1	2	0.5	0.015	8	32	2	32
LAD203	48	1	2	0.5	0.015	8	32	2	32
LAD204	72	2	2	0.5	0.015	16	32	2	32
LAD205	96	2	2	0.25	0.015	8	32	2	32
LAD206	120	4	2	0.5	0.03	8	32	2	32
LAD207	144	4	2	1	0.03	16	32	0.5	32
LAD208	168	4	2	1	0.03	16	16	2	32
LAD209	192	4	2	2	0.03	8	16	2	16
LAD210	216	4	2	2	0.03	8	16	1	32
LAD211	240	4	2	2	0.03	8	16	2	32

^aMICs to vancomycin and other antibiotic of interest are listed for each isolate. VAN, vancomycin; LZD, linezolid; DAP, daptomycin; RIF, rifampin, LEV, levofloxacin; CIP, ciprofloxacin; GEN, gentamicin; NAF, nafcillin.